Tag: NIH
Vaxxas to develop first room-temperature stable RSV vaccine with NIH license
Vaxxas, a clinical-stage biotechnology company known for its innovative high-density microarray patch (HD-MAP) vaccination platform, has secured a worldwide license from the United States National Institutes of Health (NIH) for a next-generation vaccine antigen aimed at combating Respiratory Syncytial Virus (RSV).
Featured Article
Data-rich or data-poor: Where should manufacturers focus their AI efforts?
Over the past year, manufacturers worldwide have made significant strides in adopting artificial intelligence technologies, moving beyond the initial hype to tangible implementations that deliver real business value.
